Why the study?
Ca2+ leak from sarcoplasmic reticulum via hyperactive RyR2 channels is pro-arrhythmic, prompting the use of FRET to understand the molecular mechanism driving DPc10-CaM interdependence when binding RyR2.
DPc10 alters the structural relationship and binding affinity of Calmodulin to the cardiac ryanodine receptor, providing mechanistic insights into the pathologically leaky state of RyR2.
Answers are grounded in this paper and cite their sources.
Advances biosensor for RyR2-targeted screening; leaves open clinical translation to antiarrhythmic therapy.
Ca 2+ leak from cardiomyocyte sarcoplasmic reticulum (SR) via hyperactive resting cardiac ryanodine receptor channels (RyR2) is pro-arrhythmic. An exogenous peptide, (DPc10) detects leaky RyR2 in cardiomyocytes. Conversely, calmodulin (CaM) inhibits RyR2 leak. These observations have led to designing a FRET biosensor for drug discovery targeting RyR2. Here we used FRET to understand the molecular mechanism driving the DPc10-CaM interdependence when binding RyR2 in SR vesicles. We used donor-FKBP12.6 (D-FKBP) to resolve RyR2 binding of acceptor-CaM (A-CaM). In low nanomolar Ca 2+ , DPc10 decreased both FRET max (under saturating [A-CaM]) and the CaM/RyR2 binding affinity. In micromolar Ca 2+ , DPc10 decreased FRET max without affecting CaM/RyR2 binding affinity. This correlates with analysis of fluorescence-lifetime-detected FRET indicating that DPc10 lowers occupancy of the RyR2 CaM-binding sites in nanomolar (not micromolar) Ca 2+ and lengthens D-FKBP/A-CaM distances independent of [Ca 2+ ]. To observe DPc10/RyR2 binding, we used acceptor-DPc10 (A-DPc10). CaM weakens A-DPc10/RyR2 binding, this effect being larger in micromolar vs. nanomolar Ca 2+ . Moreover, A-DPc10/RyR2 binding is cooperative in CaM- and FKBP-dependent manner, suggesting that both endogenous modulators promote concerted structural changes between RyR2 protomers for channel regulation. Aided by analysis of cryo-EM structures, these insights inform further development of the DPc10-CaM paradigm for therapeutic discovery targeting RyR2.
No takes yet. Share an insight, caveat, or question.
Svensson et al. (2023) studied Cardiac Ryanodine Receptor (RyR2) pathologically leaky state. DPc10 peptide vs. No DPc10 was evaluated on CaM/RyR2 binding affinity (Kd) and FRET max (Emax).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: